Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance
Pharmaceuticals,
Год журнала:
2025,
Номер
18(1), С. 75 - 75
Опубликована: Янв. 10, 2025
Recent
developments
in
single-cell
multi-omics
technologies
have
provided
the
ability
to
identify
diverse
cell
types
and
decipher
key
components
of
tumor
microenvironment
(TME),
leading
important
advancements
toward
a
much
deeper
understanding
how
heterogeneity
contributes
cancer
progression
therapeutic
resistance.
These
are
able
integrate
data
from
molecular
genomic,
transcriptomic,
proteomics,
metabolomics
studies
cells
at
resolution
scale
that
give
rise
full
cellular
complexity
TME.
Understanding
complex
sometimes
reciprocal
relationships
among
cells,
CAFs,
immune
ECs
has
led
novel
insights
into
their
immense
functions,
which
can
consequences
on
behavior.
In-depth
uncovered
evasion
mechanisms,
including
exhaustion
T
metabolic
reprogramming
response
hypoxia
cells.
Single-cell
also
revealed
resistance
such
as
stromal
cell-secreted
factors
physical
barriers
extracellular
matrix.
Future
examining
specific
pathways
targeting
approaches
reduce
TME
will
likely
lead
better
outcomes
with
immunotherapies,
drug
delivery,
etc.,
for
treatments.
incorporate
data,
spatial
micro-environments,
translation
personalized
therapies.
This
review
emphasizes
provide
TME,
revealing
reprogramming,
influences.
aim
guide
development
targeted
therapies,
highlighting
role
diversity
shaping
behavior
treatment
outcomes.
Язык: Английский
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Cancer Letters,
Год журнала:
2024,
Номер
unknown, С. 217350 - 217350
Опубликована: Ноя. 1, 2024
Pancreatic
cancer
remains
one
of
the
most
challenging
malignancies
to
treat
due
its
late-stage
diagnosis,
aggressive
progression,
and
high
resistance
existing
therapies.
This
review
examines
latest
advancements
in
early
detection,
therapeutic
strategies,
with
a
focus
on
emerging
biomarkers,
tumor
microenvironment
(TME)
modulation,
integration
artificial
intelligence
(AI)
data
analysis.
We
highlight
promising
including
microRNAs
(miRNAs)
circulating
DNA
(ctDNA),
that
offer
enhanced
sensitivity
specificity
for
early-stage
diagnosis
when
combined
multi-omics
panels.
A
detailed
analysis
TME
reveals
how
components
such
as
cancer-associated
fibroblasts
(CAFs),
immune
cells,
extracellular
matrix
(ECM)
contribute
therapy
by
creating
immunosuppressive
barriers.
also
discuss
interventions
target
these
components,
aiming
improve
drug
delivery
overcome
evasion.
Furthermore,
AI-driven
analyses
are
explored
their
potential
interpret
complex
data,
enabling
personalized
treatment
strategies
real-time
monitoring
response.
conclude
identifying
key
areas
future
research,
clinical
validation
regulatory
frameworks
AI
applications,
equitable
access
innovative
comprehensive
approach
underscores
need
integrated,
outcomes
pancreatic
cancer.
Язык: Английский
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy
Cellular Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 25, 2025
Tumor-infiltrating
myeloid
cells
(TIMs),
which
encompass
tumor-associated
macrophages
(TAMs),
neutrophils
(TANs),
myeloid-derived
suppressor
(MDSCs),
and
dendritic
(TADCs),
are
of
great
importance
in
tumor
microenvironment
(TME)
integral
to
both
pro-
anti-tumor
immunity.
Nevertheless,
the
phenotypic
heterogeneity
functional
plasticity
TIMs
have
posed
challenges
fully
understanding
their
complexity
roles
within
TME.
Emerging
evidence
suggested
that
presence
is
frequently
linked
prevention
cancer
treatment
improvement
patient
outcomes
survival.
Given
pivotal
function
TME,
recently
been
recognized
as
critical
targets
for
therapeutic
approaches
aimed
at
augmenting
immunostimulatory
cell
populations
while
depleting
or
modifying
those
immunosuppressive.
This
review
will
explore
important
properties
related
immunity,
angiogenesis,
metastasis.
We
also
document
latest
strategies
targeting
preclinical
clinical
settings.
Our
objective
illustrate
potential
immunological
may
improve
existing
treatments.
Язык: Английский
Dual roles of myeloid-derived suppressor cells in various diseases: a review
Archives of Pharmacal Research,
Год журнала:
2024,
Номер
47(7), С. 597 - 616
Опубликована: Июль 1, 2024
Язык: Английский
Myeloid-Derived Suppressor Cells: Implications in Cancer Immunology and Immunotherapy
Frontiers in Bioscience-Landmark,
Год журнала:
2025,
Номер
30(3)
Опубликована: Март 20, 2025
Myeloid-derived
suppressor
cells
(MDSCs)
are
believed
to
be
key
promoters
of
tumor
development
and
recognized
as
a
hallmark
cancer
cells’
ability
evade
the
immune
system
evasion.
MDSC
levels
often
increase
in
peripheral
blood
microenvironment
(TME).
These
exert
immunosuppressive
functions,
weakening
anticancer
surveillance
system,
part
by
repressing
T-cell
immunity.
Moreover,
MDSCs
may
promote
progression
interact
with
cells,
increasing
expansion
favoring
an
immunotolerant
TME.
This
review
analyzes
primary
roles
immunity,
discusses
urgent
need
develop
effective
MDSC-targeted
therapies,
highlights
potential
synergistic
combination
targeting
chimeric
antigen
receptors
checkpoint
inhibitors.
Язык: Английский
MiR- 150 deletion promotes lung tumor growth by upregulating P-STAT3 and ROS in MDSCs
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Апрель 15, 2025
Язык: Английский
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2025,
Номер
44(1)
Опубликована: Апрель 25, 2025
Abstract
This
review
discusses
reprogramming
the
breast
tumor
immune
microenvironment
from
an
immunosuppressive
cold
state
to
immunologically
active
hot
state.
A
complex
interplay
is
revealed,
in
which
accumulation
of
metabolic
byproducts—such
as
lactate,
reactive
oxygen
species
(ROS),
and
ammonia—is
shown
impair
T-cell
function
promote
escape.
It
demonstrated
that
(TME)
dominated
by
cytokines,
including
interleukin-10
(IL-10),
transforming
growth
factorβ
(TGFβ),
IL-35.
Notably,
IL-35
produced
regulatory
T
cells
cancer
cells.
The
conversion
conventional
into
IL-35-producing
induced
cells,
along
with
inhibition
pro-inflammatory
cytokine
secretion,
contributes
suppression
anti-tumor
immunity.
further
key
checkpoint
molecules—such
PD-1,
PDL1,
CTLA-4,
TIM-3,
LAG-3,
TIGIT—are
upregulated
within
TME,
leading
Tcell
exhaustion
diminished
responses.
blockade
these
checkpoints
restore
functionality
proposed
a
strategy
convert
tumors
ones
robust
effector
cell
infiltration.
therapeutic
potential
chimeric
antigen
receptor
(CAR)T
therapy
also
explored,
targeting
specific
tumor-associated
antigens,
such
glycoproteins
tyrosine
kinases,
highlighted.
suggested
CART
efficacy
can
be
enhanced
combining
inhibitors
other
immunomodulatory
agents,
thereby
overcoming
barriers
imposed
TME.
Moreover,
role
microbiome
regulating
estrogen
metabolism
systemic
inflammation
reviewed.
Alterations
gut
microbiota
are
affect
microbiome-based
interventions
additional
means
facilitate
cold-to-hot
transition.
concluded
immunological
pathways
underpin
suppression—through
combination
strategies
involving
blockade,
therapies,
modulation—the
TME
achieved.
anticipated
enhance
infiltration
function,
improving
overall
immunotherapies
better
clinical
outcomes
for
patients.
Язык: Английский
The role of exosomes in bladder cancer immunotherapy
Journal of the National Cancer Center,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 1, 2025
Язык: Английский
Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
Progress in molecular biology and translational science,
Год журнала:
2024,
Номер
unknown, С. 1 - 60
Опубликована: Янв. 1, 2024
Язык: Английский
FloraStilbene: immunotherapy adjuvant for breast cancer
Journal of Stem Cell Research & Therapeutics,
Год журнала:
2024,
Номер
9(1), С. 45 - 53
Опубликована: Янв. 1, 2024
Despite
significant
advancements
in
therapeutic
approaches
to
triple-negative
breast
cancer,
treatments
remain
relatively
ineffective
once
metastasis
occurs.
The
introduction
of
immunotherapy
has
revolutionized
oncological
therapies,
yet
hurdles
before
its
full
potential
can
be
realized.
In
this
review,
we
examine
immune
escape
mechanisms
shared
between
pregnancy
(the
'fetal
allograft')
and
cancer.
We
discuss
the
use
abortion-inducing
agents
context
cancer
immunotherapy,
also
provide
rationale
preliminary
data
on
FloraStilbene™,
a
combination
polyphenol
antioxidant
pterostilbene
glucocorticoid
receptor
antagonist
mifepristone,
for
stimulation
anticancer
immunity.
Язык: Английский